NTHI

Pediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development Strategy Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy with an aggressive brain tumor who, after receiving investigational intranasal NEO100 through NeOnc's Compassionate Care program, is breathing independently without ventilator support and beginning to move his legs.

CALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company's Compassionate Care program.

CALABASAS, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Amir F.

NeOnc (NASDAQ:NTHI) is strengthening its boardroom, as its clinical-development progress seeks to advance treatments for some of the most difficult cancers

CALABASAS, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, today announced the appointment of Ali Alabedin to its Board of Directors, effective October 9, 2026.

DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com )-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for hope.

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- A fall calendar is bringing NeOnc Technologies Holdings' (NASDAQ: NTHI) investigational brain-cancer programs into focus. Anticipation is building as Roth Capital's recent Buy initiation adds another Wall Street voice to the NTHI story.

DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212, its oral perillyl alcohol-temozolomide conjugate being developed for aggressive central nervous system cancers.

NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.

CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.